{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:56:20Z","timestamp":1793156180693,"version":"4.5.0"},"reference-count":59,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:sec id=\"ab-crv260001-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Circulating tumor DNA (ctDNA) has emerged as a noninvasive biomarker with the potential to detect minimal residual disease (MRD), monitor treatment response, and identify recurrence (eg, molecular relapse) earlier than conventional clinical or imaging approaches. Although ctDNA-based MRD assays have demonstrated prognostic value in early breast cancer, their optimal clinical utility remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-crv260001-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>This review summarizes the current data on ctDNA MRD assays in early breast cancer. Although these assays have established analytical and clinical validity, their clinical utility remains uncertain. Dynamics of ctDNA during neoadjuvant therapy are associated with pathologic complete response and long-term outcomes. Following completion of curative-intent therapy, ctDNA positivity (eg, presence of MRD) is strongly associated with future distant recurrence. Similarly, the emergence of ctDNA during surveillance precedes the clinical diagnosis of overt metastatic disease. Although observational studies and meta-analyses have supported ctDNA as a complementary biomarker for established risk-stratification tools, evidence that demonstrates improved outcomes with ctDNA-guided management remains limited. Furthermore, the optimal timing and frequency of testing remain unknown, and studies comparing assays are lacking. Multiple ongoing prospective interventional trials are evaluating whether ctDNA-guided treatment escalation or de-escalation can improve patient outcomes and support the routine implementation of ctDNA assays in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-crv260001-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>ctDNA-based MRD assays hold promise for refining risk stratification, enabling earlier detection of recurrence, and informing treatment decisions in patients with early breast cancer, but clinical utility has not yet been demonstrated. Prospective trials are essential to determine whether ctDNA-guided interventions improve outcomes beyond standard management. Clinicians should understand the strengths, limitations, and evolving evidence base of ctDNA assays, as well as patient preferences, prior to incorporating them into patient care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.1465","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T15:30:30Z","timestamp":1779982230000},"page":"773","source":"Crossref","is-referenced-by-count":8,"title":["Circulating Tumor DNA in Early Breast Cancer"],"prefix":"10.1001","volume":"12","author":[{"given":"Ilana","family":"Schlam","sequence":"first","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Parsons","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Morganti","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Broad Institute of MIT and Harvard, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"crv260001r1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer.","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"crv260001r2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","article-title":"Overall survival with abemaciclib in early breast cancer.","volume":"37","author":"Johnston","year":"2026","journal-title":"Ann Oncol"},{"key":"crv260001r3","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer.","volume":"394","author":"Loibl","year":"2026","journal-title":"N Engl J Med"},{"issue":"18","key":"crv260001r4","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment.","volume":"379","author":"Corcoran","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"crv260001r5","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1182\/blood.V85.6.1416.bloodjournal8561416","article-title":"Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance.","volume":"85","author":"Campana","year":"1995","journal-title":"Blood"},{"key":"crv260001r6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.667397","article-title":"Therapeutic targeting of minimal residual disease to prevent late recurrence in hormone-receptor positive breast cancer: challenges and new approaches.","volume":"11","author":"Cescon","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"crv260001r7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology.","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat Rev Genet"},{"issue":"1","key":"crv260001r8","doi-asserted-by":"publisher","first-page":"9945","DOI":"10.1038\/s41467-025-65432-5","article-title":"Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.","volume":"16","author":"Magbanua","year":"2025","journal-title":"Nat Commun"},{"issue":"3","key":"crv260001r9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2159-8290.CD-22-0692","article-title":"Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes.","volume":"13","author":"De Sarkar","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"crv260001r10","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41467-023-36801-9","article-title":"Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer.","volume":"14","author":"Prat","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"crv260001r11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PLoS One"},{"issue":"548","key":"crv260001r12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz8084","article-title":"ctDNA monitoring using patient-specific sequencing and integration of variant reads.","volume":"12","author":"Wan","year":"2020","journal-title":"Sci Transl Med"},{"issue":"302","key":"crv260001r13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"issue":"3","key":"crv260001r14","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1101\/gr.209601.116","article-title":"UMI-tools: modeling sequencing errors in unique molecular identifiers to improve quantification accuracy.","volume":"27","author":"Smith","year":"2017","journal-title":"Genome Res"},{"issue":"8","key":"crv260001r15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1158\/1538-7445.AM2025-692","article-title":"Abstract 692: Analytical validation of a tissue-free epigenomic assay for circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection in early-stage cancer.","volume":"85","author":"Quinn","year":"2025","journal-title":"Cancer Res"},{"key":"crv260001r16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.18632\/oncotarget.28565","article-title":"Analytical validation of NeXT Personal, an ultra-sensitive personalized circulating tumor DNA assay.","volume":"15","author":"Northcott","year":"2024","journal-title":"Oncotarget"},{"issue":"8","key":"crv260001r17","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41416-022-01716-7","article-title":"Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)\u2014a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma.","volume":"126","author":"Flach","year":"2022","journal-title":"Br J Cancer"},{"issue":"8","key":"crv260001r18","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-24-3472","article-title":"Ultrasensitive detection and monitoring of circulating tumor DNA using structural variants in early-stage breast cancer.","volume":"31","author":"Elliott","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"13","key":"crv260001r19","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1158\/1538-7445.AM2018-4542","article-title":"Abstract 4542: analytical validation of the SignateraTM RUO assay, a highly sensitive patient-specific multiplex PCR NGS-based noninvasive cancer recurrence detection and therapy monitoring assay.","volume":"78","author":"Sethi","year":"2018","journal-title":"Cancer Res"},{"issue":"16","key":"crv260001r20","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1200\/JCO.2025.43.16_suppl.3142","article-title":"Clinical performance of Signatera Genome assay in a cohort of patients (pts) with solid tumors","volume":"43","author":"George","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"crv260001r21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0302129","article-title":"Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors.","volume":"19","author":"Zollinger","year":"2024","journal-title":"PLoS One"},{"issue":"1","key":"crv260001r22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/jso.27989","article-title":"Circulating tumor DNA as a marker of recurrence risk in stage III colorectal cancer: the a-CORRECT Study.","volume":"132","author":"Diergaarde","year":"2025","journal-title":"J Surg Oncol"},{"issue":"22","key":"crv260001r23","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor\u2013positive advanced breast cancer.","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"crv260001r24","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"issue":"466","key":"crv260001r25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced detection of circulating tumor DNA by fragment size analysis.","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci Transl Med"},{"issue":"7732","key":"crv260001r26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41586-018-0703-0","article-title":"Sensitive tumour detection and classification using plasma cell-free DNA methylomes.","volume":"563","author":"Shen","year":"2018","journal-title":"Nature"},{"issue":"13","key":"crv260001r27","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1158\/1078-0432.CCR-24-3335","article-title":"Characterization of plasma cell\u2013free DNA variants as of tumor or clonal hematopoiesis origin in 16,812 advanced cancer patients.","volume":"31","author":"Magee","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"6","key":"crv260001r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105286","article-title":"Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer.","volume":"10","author":"Elliott","year":"2025","journal-title":"ESMO Open"},{"issue":"6","key":"crv260001r29","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer.","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"crv260001r30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140712","article-title":"Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA.","volume":"10","author":"Lanman","year":"2015","journal-title":"PLoS One"},{"key":"crv260001r31","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-PS2-07-06","article-title":"Abstract PS2-07-06: prevalence and dynamics of circulating tumor DNA among patients with triple-negative breast cancer undergoing preoperative systemic therapy with or without immunotherapy.","volume":"32","author":"Yoo","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"3","key":"crv260001r32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10549-024-07508-2","article-title":"Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer.","volume":"209","author":"Garcia-Murillas","year":"2025","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"crv260001r33","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.annonc.2025.01.021","article-title":"Whole genome sequencing-powered ctDNA sequencing for breast cancer detection.","volume":"36","author":"Garcia-Murillas","year":"2025","journal-title":"Ann Oncol"},{"issue":"4","key":"crv260001r34","doi-asserted-by":"publisher","first-page":"PD7","DOI":"10.1158\/1557-3265.SABCS25-PD7-10","article-title":"Abstract PD7-10: NeoN: three year event free survival (EFS) and ultrasensitive ctDNA dynamics in early triple negative breast cancer (TNBC) treated with neoadjuvant carboplatin\/paclitaxel and nivolumab.","volume":"32","author":"Loi","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"6","key":"crv260001r35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","article-title":"Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.","volume":"41","author":"Magbanua","year":"2023","journal-title":"Cancer Cell"},{"issue":"10","key":"crv260001r36","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.annonc.2023.08.004","article-title":"Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.","volume":"34","author":"Parsons","year":"2023","journal-title":"Ann Oncol"},{"key":"crv260001r37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02934","article-title":"The pathologic response evaluation and detection in circulating tumor-DNA study: ultrasensitive circulating tumor-DNA assessment of breast cancer minimal residual disease.","volume":"JCO2502934","author":"Hunter","year":"2026","journal-title":"J Clin Oncol"},{"issue":"11","key":"crv260001r39","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1158\/1078-0432.CCR-19-3005","article-title":"Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer.","volume":"26","author":"Parsons","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"crv260001r40","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00456","article-title":"Serial postoperative circulating tumor DNA assessment has strong prognostic value during long-term follow-up in patients with breast cancer.","volume":"8","author":"Shaw","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"16","key":"crv260001r41","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1200\/JCO.2025.43.16_suppl.3055","article-title":"Circulating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: an updated analysis of the CHiRP study.","volume":"43","author":"Yoo","year":"2025","journal-title":"J Clin Oncol"},{"issue":"22","key":"crv260001r42","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1200\/JCO.22.00908","article-title":"Circulating tumor DNA and late recurrence in high-risk hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative breast cancer.","volume":"40","author":"Lipsyc-Sharf","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"crv260001r43","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","article-title":"Assessment of molecular relapse detection in early-stage breast cancer.","volume":"5","author":"Garcia-Murillas","year":"2019","journal-title":"JAMA Oncol"},{"issue":"17","key":"crv260001r44","doi-asserted-by":"publisher","first-page":"LBA507","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA507","article-title":"Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).","volume":"42","author":"Loi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"crv260001r46","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.","volume":"34","author":"Turner","year":"2023","journal-title":"Ann Oncol"},{"key":"crv260001r47","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-GS3-01","article-title":"Abstract GS3-01: Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w\/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy.","volume":"31","author":"Turner","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"16","key":"crv260001r48","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1200\/JCO.2025.43.16_suppl.1010","article-title":"Circulating tumor (ct)DNA monitoring of ER+\/HER2- high-risk breast cancer during adjuvant endocrine therapy.","volume":"43","author":"Pusztai","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"crv260001r49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41523-024-00708-5","article-title":"Adjuvant endocrine therapy with cyclin-dependent kinase 4\/6 inhibitor, ribociclib, for localized hormone receptor-positive\/HER2- breast cancer (LEADER).","volume":"11","author":"Spring","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"crv260001r50","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS25-PD5-01","article-title":"Abstract PD5-01: personalized circulating tumor DNA (ctDNA) testing, intervention, and temporal dynamics in ER+\/HER2- early-stage breast cancer (LEADER).","volume":"32","author":"Medford","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"1","key":"crv260001r51","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1038\/s41467-025-56658-4","article-title":"Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay.","volume":"16","author":"Elliott","year":"2025","journal-title":"Nat Commun"},{"issue":"16","key":"crv260001r52","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1200\/JCO.2025.43.16_suppl.100","article-title":"Performance evaluation of a reflex blood-based methylated ctDNA multi-cancer early detection test in individuals with obesity","volume":"43","author":"Kurbegov","year":"2025","journal-title":"J Clin Oncol"},{"key":"crv260001r53","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-PS9-08","article-title":"Abstract PS9-08: ultra-sensitive detection of circulating tumor DNA (ctDNA) in patients (pts) undergoing neoadjuvant endocrine therapy for hormone receptor\u2013positive (HR+) early breast cancer (BC).","volume":"31","author":"Grinshpun","year":"2025","journal-title":"Clin Cancer Res"},{"key":"crv260001r54","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-GS1-06","article-title":"Abstract GS1-06: circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2\u2013positive (HER2[+]) early breast cancer (EBC): translational analysis of PHERGain neoadjuvant tailored treatment study.","volume":"32","author":"Llombart-Cussac","year":"2026","journal-title":"Clin Cancer Res"},{"key":"crv260001r55","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-RF3-04","article-title":"Abstract RF3-04: tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial.","volume":"32","author":"Parsons","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"11","key":"crv260001r56","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105858","article-title":"Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.","volume":"10","author":"Crown","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"crv260001r57","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1038\/s41467-024-46961-x","article-title":"Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.","volume":"15","author":"Lynce","year":"2024","journal-title":"Nat Commun"},{"issue":"16","key":"crv260001r58","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.2024.42.16_suppl.588","article-title":"Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel\/trastuzumab\/pertuzumab (THP) in the DAPHNe trial.","volume":"42","author":"Waks","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"crv260001r59","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/1078-0432.CCR-23-2326","article-title":"Comparison of circulating tumor DNA assays for molecular residual disease detection in early-stage triple-negative breast cancer.","volume":"30","author":"Coakley","year":"2024","journal-title":"Clin Cancer Res"},{"key":"crv260001r38","author":"Balic","year":"2025"},{"key":"crv260001r45","author":"Parsons","year":"2025"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2849592\/jamaoncology_schlam_2026_rv_260001_1784081552.47419.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:00:51Z","timestamp":1784214051000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2849592"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.1465","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}